Table 1

 Demographics, disease characteristics and clinimetry data of 68 patients included in the early spondyloarthritis clinic cohort

Characteristic% of patientsClinimetryClinimetry data
ASQoL, ankylosing spondylitis quality of life; BASDAI, Bath Ankylosing Spondylitis Activity Index; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; DMARD, disease-modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate; HLA-B27, human leucocyte antigen B27; IBD, inflammatory bowel disease; IQR, interquartile range; MASES, Maastricht Ankylosing Spondylitis Enthesopathy Index; NSAID, non-steroidal anti-inflammatory drug; VAS, visual analogue scale.
*Figures are means (standard deviations) unless otherwise indicated. ‡History or presence of this symptom (% of patients).
Male38Spinal pain the past week (on a 10-cm VAS)4.7 (2.6)*
HLA-B27+46Night pain (on a Likert scale (0–3))0:18%; 1:40%; 2:38%; 3:4%
IBD‡15Global well-being the past week (on a 10 cm VAS)3.8 (3.8)
Uveitis§15Duration of morning stiffness the past week (in min; median (IQR))23 (10; 60)
Psoriasis§24Severity of fatigue the past week (on a 10 cm VAS)4.5 (2.6)
Family history of AS§5444-swollen joint count0.19 (0.6)
Dactylitis§10Finger to floor distance (in cm; median (IQR))0.0 (0–12.5)
Heel pain§6Chest expansion (in cm; % of patients <4 cm)4.9 (2.0; 43%)
Peripheral arthritis§28Lateral spinal flexion (in cm; % of patients <20 cm)15.2 (4.8; 90%)
IBP improving with NSAIDs§59Modified Schober (in cm; % of patients <5 cm)15.0 (1.1; 50%)
Buttock pain§71Occiput-to-wall distance (in cm; % of patients >0 cm)0.4 (1.7; 7%)
Current NSAID use43Cervical rotation (in°; % of patients <70°)73 (14; 32%)
Current DMARD use9BASDAI3.6 (2.1)
Current glucocorticoid use1.5BASFI2.6 (2.1)
Current use of IBD-related drugs6BASMI1.1 (1.2)
Criteria for inflammatory low-back pain:MASES2.8(2.4)
3 Criteria present3ASQoL6.4 (4.8)
4 Criteria present41ESR; in mm; median (IQR))6 (4; 16)
5 Criteria present56CRP (in mg/l; median (IQR))7 (3; 9)
Patients with raised acute-phase reactants (in %)41